BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Orthop. Nov 18, 2026; 17(11): 126620
Published online Nov 18, 2026. doi: 10.5312/wjo.126620
Table 2 Dosing regimens of bypassing agents in people with hemophilia with inhibitors aged > 65 years
Drug
Dosing for minor orthopedic surgery
Dosing for major orthopedic surgery
Comments
Recombinant factor VII activated90 µg/kg/dose immediately before surgery and every 2 hours for 2 days and then every 2-6 hours until healed90 µg/kg/dose immediately before surgery and every 2 hours for 2 days. Then every 2-3 hours for 5 days, then every 4 hours until days 7-10, then every 6 hours until days 14-21Preferred drug for individuals with hemophilia B and high-titer inhibitors per WFH guidelines since aPCCs contains factor IX and may cause or worsen an allergic reaction
For individuals with factor IX deficiency, low dose (15-30 µg/kg) in combination with tranexamic acid has been shown to be effective for major surgery in limited studies and can be considered for those at risk of thrombosis
aPCCs50-100 U/kg immediately prior to surgery and then every 6-12 hours50-100 U/kg immediately prior to surgery, then every 6-12 hoursMaximum: 100 units/kg/dose; 200 units/kg/day)
Less preferred for hemophilia B individuals with high-titer inhibitors per WFH guidelines


Write to the Help Desk